SCYX News and Press, SCYNEXIS Inc. From 05/14/21

SCYNEXIS ([[SCYX]] +3.2%) secured a $60M term loan facility with Hercules Capital (HTGC) and Silicon Valley Bank for strengthening its balance sheet ahead of the anticipated commercial launch of Brexafemme, the expected trade name for ibrexafungerp, an oral antifungal product candidate f...

Together with SCYNEXIS’ $93M cash balance at 12/31/20, the non-dilutive capital injections from this term loan, the recent licensing payments from Hansoh Pharma, and the monetization of 2020 New Jersey NOLs further strengthen SCYNEXIS’ balance sheet and projected cash ru...

SCYNEXIS (SCYX) announces the appointment of Christine Coyne as the company's chief commercial officer, effective May 10, 2021.Coyne joins SCYNEXIS with 30 years of experience in launch and commercialization of products across multiple therapeutic areas.Most recently, ...

Strengthening the management team with deep anti-infective commercial expertise across hospital and community settings ahead of anticipated approval of Brexafemme (ibrexafungerp) in June 2021 and H2:2021 launch JERSEY CITY, N.J., May 11, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (...

A single-day dose of oral ibrexafungerp demonstrates positive clinical outcomes in difficult-to-treat vulvovaginal candidiasis (VVC) patient populations: those with non- albicans Candida VVC and/or severe VVC Brexafemme, the expected trade name for ibrexafungerp, an oral...

JERSEY CITY, N.J., April 20, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that two data sets from the Company’s Phase 3 VA...

SCYNEXIS (SCYX): FY GAAP EPS of -$5.15 misses by $3.39.Cash and cash equivalents of $93.0MShares are up 3.79% PM.Press Release For further details see: SCYNEXIS EPS misses by $3.39

FDA accepted SCYNEXIS’ New Drug Application (NDA) for oral ibrexafungerp for the treatment of vaginal yeast infections, conditionally approved the brand name Brexafemme TM , and granted priority review with a PDUFA target action date of June 1, 2021 SCYNEX...

Scynexis (SCYX) perks up 6% premarket on positive results from the interim efficacy analysis of Phase 3 FURI study and Phase 3 CARES study. In FURI study, antifungal activity was consistently positive across all interim analyses with oral ibrexafungerp showing clinical benefit in 30...

Consistent with prior two interim analyses, FURI results confirm positive clinical activity of oral ibrexafungerp in patients with difficult-to-treat, severe, mucocutaneous and invasive fungal infections, including those caused by resistant strains 1 st Interim a...